
    
      This is a randomized, placebo-controlled, double-blind pilot study to investigate the effects
      of GRF6021, a 5% human plasma protein fraction administered by intravenous (IV) infusion, on
      intracellular signaling cascades in blood leukocytes in subjects undergoing primary hip or
      knee arthroplasty.
    
  